Claims for Patent: 7,807,799
✉ Email this page to a colleague
Summary for Patent: 7,807,799
Title: | Reducing protein A leaching during protein A affinity chromatography |
Abstract: | A method for reducing leaching of protein A during protein A affinity chromatography is described which involves reducing temperature or pH of, or by adding one or more protease inhibitors to, a composition that is subjected to protein A affinity chromatography. |
Inventor(s): | Fahrner; Robert L. (San Mateo, CA), Laverdiere; Amy (San Francisco, CA), McDonald; Paul J. (San Francisco, CA), O\'Leary; Rhona M. (San Francisco, CA) |
Assignee: | Genentech, Inc. (South San Francisco, CA) |
Application Number: | 12/269,752 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,807,799 |
Patent Claims: | 1. A method of purifying a protein which comprises a C.sub.H2/C.sub.H3 region, comprising subjecting a composition comprising said protein to protein A affinity
chromatography at a temperature in the range from about 10 .degree. C. to about 18 .degree. C.
2. The method of claim 1 further comprising exposing the composition subjected to protein A affinity chromatography to a protease inhibitor. 3. The method of claim 2 wherein the protease inhibitor is EDTA or 4-(2-aminoethyl)-benzenesulfonyl-fluoride, hydrochloride (AEBSF). 4. The method of claim 2 comprising adjusting the pH of the composition prior to protein A affinity chromatography to a pH in the range from about 2.5 to about 3.5. 5. The method of claim 1 wherein the protein is an antibody. 6. The method of claim 5 wherein the antibody binds an antigen selected from the group consisting of HER2, vascular endothelial growth factor (VEGF), IgE, CD20, CD40, CD11a, tissue factor (TF), prostate stem cell antigen (PSCA), interleukin-8(IL-8), epidermal growth factor receptor (EGFR), HER3, HER4, .alpha.4.beta.7 and .alpha.5.beta.3. 7. The method of claim 5 wherein the antibody is selected from the group consisting of Trastuzumab, humanized 2C4, humanized CD11a antibody, and humanized VEGF antibody. 8. The method of claim 5 wherein the antibody binds HER2antigen. 9. The method of claim 8 wherein the antibody is Trastuzumab or humanized 2C4. 10. The method of claim 1 wherein the protein is an immunoadhesin. 11. The method of claim 10 wherein the immunoadhesin is a TNF receptor immunoadhesin. 12. A method of purifying a protein which comprises a C.sub.H2/C.sub.H3 region comprising: a. subjecting a composition comprising said protein to protein A affinity chromatography to provide a recovered composition and measuring leached protein A in said recovered composition; b. if greater than about 20 ng protein A per mg of said protein is measured in said recovered composition, then performing subsequent purification of compositions comprising said protein by protein A affinity chromatography at a temperature in the range from about 10.degree. C. to about 18.degree. C., such that protein A leaching is reduced; and c. exposing the composition subjected to protein A affinity chromatography to a protease inhibitor in order to reduce the protease activity and further reduce leaching of protein A. |
Details for Patent 7,807,799
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2023-07-28 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2023-07-28 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2023-07-28 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.